Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis

Toxicological Sciences

Volumn 142, Issue 1, 2014, Pages 45-55

  Hardwick, Rhiannon N ^a   Clarke, John D ^a   Lake, April D ^a   Canet, Mark J ^a   Anumol, Tarun ^b   Street, Stephanie M ^a   Merrell, Matthew D ^a   Goedken, Michael J ^c   Snyder, Shane A ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

ABC transporters; Adverse drug reactions; Hepatobiliary disposition; Hepatotoxicity; Methotrexate

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHOLINE; METHIONINE; METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; ABC TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY HYPERPLASIA; BILIARY TRACT DISEASE; BLOOD; CELL DEATH; CONTROLLED STUDY; DIARRHEA; DRUG DISPOSITION; DRUG MEGADOSE; DRUG SENSITIVITY; FECES; GASTROINTESTINAL TOXICITY; HISTOLOGY; HYPERPLASIA; IMMUNOBLOTTING; INFLAMMATION; INTESTINE INJURY; INTESTINE VILLUS ATROPHY; LIPID STORAGE; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER REGENERATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; URINARY EXCRETION; URINE; ANIMAL; CHEMISTRY; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KIDNEY; LIVER; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FECES; KIDNEY; LIVER; MALE; METHOTREXATE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84985034325     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu156     Document Type: Article

References (33)

1. Anstee, Q. M., Daly, A. K. and Day, C. P. (2011). Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta 1812, 1557-1566.
2. Barker, J., Horn, E. J., Lebwohl, M., Warren, R. B., Nast, A., Rosenberg, W., Smith, C. and International Psoriasis, C. (2011). Assessment and management of methotrexate hepatotoxicity in psoriasis patients: Report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J. Eur. Acad. Dermatol. Venereol. 25, 758-764.
3. Butturini, A. M., Dorey, F. J., Lange, B. J., Henry,D.W., Gaynon, P. S., Fu, C., Franklin, J., Siegel, S. E., Seibel, N. L., Rogers, P. C., et al. (2007). Obesity and outcome in pediatric acute lymphoblastic leukemia. J. Clin. Oncol. 25, 2063-2069.
4. Chen, Z. S., Lee, K., Walther, S., Raftogianis, R. B., Kuwano, M., Zeng, H. and Kruh, G. D. (2002). Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62, 3144-3150.
5. Cheung, O. and Sanyal, A. J. (2009). Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 25, 230-237.
6. Cole, P. D. and Kamen, B. A. (2000). High-dose methotrexate is lethal to rats. Why give it to children? Pediatr. Hematol. Oncol. 17, 609-613.
7. Fisher, C. D., Lickteig, A. J., Augustine, L. M., Oude Elferink, R. P., Besselsen, D. G., Erickson, R. P. and Cherrington, N. J. (2009a). Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 613, 119-127.
8. Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S. and Cherrington, N. J. (2009b). Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos. 37, 2087-2094.
9. Guo, P., Wang, X., Liu, L., Belinsky, M. G., Kruh, G. D. and Gallo, J. M. (2007). Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 43, 1789-1795.
10. Hardwick, R. N., Ferreira, D. W., More, V. R., Lake, A. D., Lu, Z., Manautou, J. E., Slitt, A. L. and Cherrington, N. J. (2013). Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 41, 554-561.
11. Hardwick, R. N., Fisher, C. D., Canet, M. J., Lake, A. D. and Cherrington, N. J. (2010). Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 38, 2293-2301.
12. Hardwick, R. N., Fisher, C. D., Canet, M. J., Scheffer, G. L. and Cherrington, N. J. (2011). Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 2395-2402.
13. Hardwick, R. N., Fisher, C. D., Street, S. M., Canet, M. J. and Cherrington, N. J. (2012). Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab. Dispos. 40, 450-460.
14. Kato, S., Ito, K., Kato, Y., Wakayama, T., Kubo, Y., Iseki, S. and Tsuji, A. (2009). Involvement of multidrug resistanceassociated protein 1 in intestinal toxicity of methotrexate. Pharm. Res. 26, 1467-1476.
15. Kitamura, Y., Hirouchi, M., Kusuhara, H., Schuetz, J. D. and Sugiyama, Y. (2008). Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J. Pharmacol. Exp. Ther. 327, 465-473.
16. Lake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki,W. T. and Cherrington, N. J. (2011). Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 1954-1960.
17. Langman, G., Hall, P. M. and Todd, G. (2001). Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J. Gastroenterol. Hepatol. 16, 1395-1401.
18. Lickteig, A. J., Fisher, C. D., Augustine, L. M., Aleksunes, L. M., Besselsen, D. G., Slitt, A. L., Manautou, J. E. and Cherrington, N. J. (2007). Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab. Dispos. 35, 1970-1978.
19. Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G. and Tiribelli, C. (2008). Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 14, 72-81.
20. McCullough, A. J. (2011). Epidemiology of the metabolic syndrome in the USA. J. Dig. Dis. 12, 333-340.
21. Mencin, A. A. and Lavine, J. E. (2011). Advances in pediatric nonalcoholic fatty liver disease. Pediatr. Clin. North Am. 58, 1375-1392.
22. Schmiegelow, K. (2009). Advances in individual prediction of methotrexate toxicity: A review. Br. J. Haematol. 146, 489-503.
23. Shibayama, Y., Ushinohama, K., Ikeda, R., Yoshikawa, Y., Motoya, T., Takeda, Y. and Yamada, K. (2006). Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 97, 1260-1266.
24. Smeland, E., Bremnes, R. M., Andersen, A., Jaeger, R., Eide, T. J., Huseby, N. E. and Aarbakke, J. (1994). Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother. Pharmacol. 34, 119-124.
25. USFDA (2012). Adverse Events Reporting System Statistics. Patient Outcomes by Year. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm10.1093/toxsci/kfu156.html. Accessed January 13, 2014.
26. Vlaming, M. L., Pala, Z., van Esch, A., Wagenaar, E., de Waart, D. R., van de Wetering, K., van der Kruijssen, C. M., Oude Elferink, R. P., van Tellingen, O. and Schinkel, A. H. (2009a). Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res. 15, 3084-3093.
27. Vlaming, M. L., Pala, Z., van Esch, A., Wagenaar, E., van Tellingen, O., de Waart, D. R., Oude Elferink, R. P., van de Wetering, K. and Schinkel, A. H. (2008). Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res. 14, 8152-8160.
28. Vlaming, M. L., van Esch, A., Pala, Z., Wagenaar, E., van de Wetering, K., van Tellingen, O. and Schinkel, A. H. (2009b). Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 8, 3350-3359.
29. Vlaming, M. L., van Esch, A., van de Steeg, E., Pala, Z., Wagenaar, E., van Tellingen, O. and Schinkel, A. H. (2011). Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab. Dispos. 39, 1338-1344.
30. Wang, Z., Zhou, Q., Kruh, G. D. and Gallo, J. M. (2011). Dosedependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab. Dispos. 39, 2155-2161.
31. Warren, R. B. and Griffiths, C. E. (2008). Systemic therapies for psoriasis: Methotrexate, retinoids, and cyclosporine. Clin. Dermatol. 26, 438-447.
32. Widemann, B. C. and Adamson, P. C. (2006). Understanding and managing methotrexate nephrotoxicity. Oncologist 11, 694-703.
33. Wilke, R. A., Lin, D.W., Roden, D. M.,Watkins, P. B., Flockhart, D., Zineh, I., Giacomini, K. M. and Krauss, R. M. (2007). Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916.